Skip header and navigation

Refine By

   MORE

7 records – page 1 of 1.

Coenzyme Q10-containing composition (Immugen) protects against occupational and environmental stress in workers of the gas and oil industry.

https://arctichealth.org/en/permalink/ahliterature182230
Source
Biofactors. 2003;18(1-4):245-54
Publication Type
Article
Date
2003
Author
Ludmila Korkina
Irina Deeva
Galina Ibragimova
Alexander Shakula
Antonio Luci
Chiara De Luca
Author Affiliation
Department of Molecular Biology, Russian State Medical University, Moscow, Russia. korkin@aha.ru
Source
Biofactors. 2003;18(1-4):245-54
Date
2003
Language
English
Publication Type
Article
Keywords
Adult
Cardiovascular Diseases - etiology - prevention & control
Coenzymes
Dietary Supplements
Emotions
Environment
Female
Humans
Industrial Oils
Leukocytes - physiology
Luminescent Measurements
Luminol - pharmacology
Male
Methionine - administration & dosage
Middle Aged
Nervous System Diseases - etiology - prevention & control
Occupational Exposure
Oxidative Stress
Peroxynitrous Acid - blood
Petroleum
Phospholipids - administration & dosage
Russia
Selenium - administration & dosage
Siberia
Superoxides - blood
Tetradecanoylphorbol Acetate - pharmacology
Ubiquinone - administration & dosage - analogs & derivatives - blood
Vitamin E - administration & dosage
Abstract
The manual workers of the gas-and-oil extraction industry are exposed to hostile environmental and occupational conditions, resulting in elevated mortality and disability, due to chronic neurological and cardiovascular diseases. We evaluated the degree of oxidative stress, often associated with these pathological features, in the blood of manual and office employees of Russian Siberian extraction plants, and their psycho-physiological conditions. Results showed increased levels of spontaneous (p
PubMed ID
14695940 View in PubMed
Less detail

Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background.

https://arctichealth.org/en/permalink/ahliterature206265
Source
J Lipid Res. 1998 Feb;39(2):286-92
Publication Type
Article
Date
Feb-1998
Author
J A Conquer
B J Holub
Author Affiliation
Department of Human Biology and Nutritional Sciences, University of Guelph, Ontario, Canada.
Source
J Lipid Res. 1998 Feb;39(2):286-92
Date
Feb-1998
Language
English
Publication Type
Article
Keywords
Arrhythmias, Cardiac - prevention & control
Blood pressure
Docosahexaenoic Acids - administration & dosage - blood - therapeutic use
Dose-Response Relationship, Drug
Fatty Acids, Nonesterified - administration & dosage - blood
Female
Heart rate
Humans
India - ethnology
Kinetics
Male
Ontario
Phospholipids - administration & dosage - blood
Thrombosis - prevention & control
Abstract
There is evidence to indicate that the high rates of coronary heart disease and myocardial infarction amongst Indians of Asian descent may be partly related to circulating nonesterified fatty acids (NEFA). As docosahexaenoic acid (DHA,22:6n-3) in NEFA form has been found to exhibit anti-platelet aggregatory and anti-arrhythmic potential in vitro, the effect of supplementary DHA was examined in healthy subjects of Asian Indian background. Furthermore, time- and dose-dependent changes in absolute levels of DHA as NEFA or phospholipid (PL) were compared. The subjects consumed 8 capsules daily of placebo (DHA-free) or low DHA (0.75 g/day)or high DHA (1.50 g/day) over 6 wks. Fasting blood samples were drawn at days 0, 21, and 42 for analysis of serum lipid/lipoprotein composition. No significant effect of DHA supplementation on the levels of serum lipid/lipoproteins (including Lp[a]) or blood pressure was found. However, the DHA level in serum phospholipid rose by 167% overall with low-dose supplementation (from 2.4-6.4 mol%) but only by an additional 23% upon doubling the dose from 0.75 g to 1.50 g/day. Furthermore, after 6 weeks of supplementation with 0.75 g or 1.5 g DHA/day, absolute concentrations of DHA as PL were not significantly different from the corresponding 3-week values. Interestingly, the absolute concentrations of serum DHA as NEFA showed a marked rise with low-dose supplementation (by 212% overall, from 2.4 to 7.5 microM) and a further 70% rise (to 12.7 microM) upon doubling the supplementation from 0.75 to 1.50 g/day. As well, the 6-week concentrations (DHA-NEFA) were significantly different than the corresponding 3-week values at both dose levels. Elevation of circulating DHA-NEFA levels via DHA supplementation, as shown herein, to concentrations that exhibit anti-thrombotic and anti-arrhythmic potential in vitro needs to be extended to trials where clinical end-points are determined.
PubMed ID
9507989 View in PubMed
Less detail

[Multiple-modality treatment of patients with psoriatic arthritis in the early stages of the disease]

https://arctichealth.org/en/permalink/ahliterature13929
Source
Lik Sprava. 2002 Jul-Sep;(5-6):56-9
Publication Type
Article
Author
V P Kvasha
Source
Lik Sprava. 2002 Jul-Sep;(5-6):56-9
Language
Ukrainian
Publication Type
Article
Keywords
Adult
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage - therapeutic use
Arthritis, Psoriatic - therapy
Combined Modality Therapy
Electrophoresis
English Abstract
Exercise Therapy
Female
Humans
Male
Middle Aged
Phospholipids - administration & dosage - therapeutic use
Synovial Membrane - surgery
Treatment Outcome
Abstract
Psoriatic arthritis is encountered in 7 to 44 percent of psoriatic cases. In managing the condition there arise certain difficulties related to our having no clear idea of the genesis of structural-and-functional changes in the locomotor system as well as in the blending of cutaneous and articular lesions. The study is based on the examination and treatment of 63 patients whose age ranged between 25 to 60 years. Instituted in the patients was a multimodality therapy with medicamentous, physiotherapeutic, and orthopedic treatments having been administered. Persistent lesion of the paraarticular tissues diagnosable clinically and by sonography techniques as well was regarded as a direct indication for sinovectomy that was performed in 8 patients. Therapeutic benefit from treatment occurred in 96 percent of patients.
PubMed ID
12442523 View in PubMed
Less detail

NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study): Randomized Controlled Contrast-Enhanced Sonothrombolysis in an Unselected Acute Ischemic Stroke Population.

https://arctichealth.org/en/permalink/ahliterature282585
Source
Stroke. 2017 Feb;48(2):335-341
Publication Type
Article
Date
Feb-2017
Author
Aliona Nacu
Christopher E Kvistad
Halvor Naess
Halvor Øygarden
Nicola Logallo
Jörg Assmus
Ulrike Waje-Andreassen
Kathinka D Kurz
Gesche Neckelmann
Lars Thomassen
Source
Stroke. 2017 Feb;48(2):335-341
Date
Feb-2017
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Brain Ischemia - diagnostic imaging - drug therapy - epidemiology
Female
Humans
Male
Middle Aged
Norway - epidemiology
Phospholipids - administration & dosage
Population Surveillance - methods
Prospective Studies
Single-Blind Method
Stroke - diagnostic imaging - drug therapy - epidemiology
Sulfur Hexafluoride - administration & dosage
Thrombolytic Therapy - methods
Tissue Plasminogen Activator - administration & dosage
Ultrasonography, Doppler, Transcranial - methods
Abstract
The NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study) aimed to assess effect and safety of contrast-enhanced ultrasound treatment in an unselected acute ischemic stroke population.
Patients treated with intravenous thrombolysis within 4.5 hours after symptom onset were randomized 1:1 to either contrast-enhanced sonothrombolysis (CEST) or sham CEST. A visible arterial occlusion on baseline computed tomography angiography was not a prerequisite for inclusion. Pulse-wave 2 MHz ultrasound was given for 1 hour and contrast (SonoVue) as an infusion for ˜30 minutes. Magnetic resonance imaging and angiography were performed after 24 to 36 hours. Primary study end points were neurological improvement at 24 hours defined as National Institutes of Health Stroke Scale score 0 or reduction of =4 National Institutes of Health Stroke Scale points compared with baseline National Institutes of Health Stroke Scale and favorable functional outcome at 90 days defined as modified Rankin scale score 0 to 1.
A total of 183 patients were randomly assigned to either CEST (93 patient) or sham CEST (90 patients). The rates of symptomatic intracerebral hemorrhage, asymptomatic intracerebral hemorrhage, or mortality were not increased in the CEST group. Neurological improvement at 24 hours and functional outcome at 90 days was similar in the 2 groups both in the intention-to-treat analysis and in the per-protocol analysis.
CEST is safe among unselected ischemic stroke patients with or without a visible occlusion on computed tomography angiography and with varying grades of clinical severity. There was, however, statistically no significant clinical effect of sonothrombolysis in this prematurely stopped trial.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT01949961.
Notes
Cites: PLoS One. 2016 Apr 14;11(4):e015289827077372
Cites: Ultrasound Med Biol. 2012 Sep;38(9):1589-9822766112
Cites: Stroke. 2010 Feb;41(2):280-720044531
Cites: Int J Stroke. 2015 Apr;10 (3):336-4225319377
Cites: Stroke. 2012 Jun;43(6):1591-522442174
Cites: Int J Stroke. 2014 Dec;9(8):1006-1025079049
Cites: J Cereb Blood Flow Metab. 2010 Oct;30(10):1712-2020531462
Cites: Cerebrovasc Dis. 2015;40(1-2):3-925998791
Cites: Stroke. 2006 Feb;37(2):425-916373632
Cites: N Engl J Med. 2007 Aug 9;357(6):572-917687132
Cites: N Engl J Med. 2008 Sep 25;359(13):1317-2918815396
Cites: Lancet. 2007 Jan 27;369(9558):275-8217258667
Cites: Cochrane Database Syst Rev. 2012 Oct 17;10:CD00834823076946
Cites: Ann Neurol. 2009 Jul;66(1):28-3819670432
Cites: BMC Neurol. 2015 Jul 11;15:11026162826
Cites: Echocardiography. 2001 Apr;18(3):259-6311322909
Cites: N Engl J Med. 2004 Nov 18;351(21):2170-815548777
Cites: Ultrasound Med Biol. 2000 Jun;26(5):889-9510942836
Cites: Ultrasound Med Biol. 2008 Oct;34(10 ):1573-718450360
Cites: Stroke. 2005 Jul;36(7):1441-615947262
Cites: Acta Neurol Scand Suppl. 2014;(198):37-4024588505
Cites: Lancet. 2014 Nov 29;384(9958):1929-3525106063
Cites: J Thromb Thrombolysis. 2005 Feb;19(1):55-915976968
Cites: BMC Neurol. 2014 May 15;14 :10624886064
Cites: Stroke. 2007 Mar;38(3):967-7317272772
Cites: J Acoust Soc Am. 2016 May;139(5):EL13527250198
Cites: J Neuroimaging. 2014 May-Jun;24(3):209-2023607713
Cites: Ultrasound Med Biol. 2005 Jul;31(7):979-8515972204
Cites: Stroke. 2008 May;39(5):1464-918356546
Cites: Stroke. 2005 Oct;36(10):2121-516151026
PubMed ID
27980128 View in PubMed
Less detail

Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults.

https://arctichealth.org/en/permalink/ahliterature258828
Source
Lipids Health Dis. 2014;13:82
Publication Type
Article
Date
2014
Author
Bodil Bjørndal
Elin Strand
Jennifer Gjerde
Pavol Bohov
Asbjørn Svardal
Bernd Wk Diehl
Sheila M Innis
Alvin Berger
Rolf K Berge
Source
Lipids Health Dis. 2014;13:82
Date
2014
Language
English
Publication Type
Article
Keywords
Adult
Animals
Dietary Supplements
Docosahexaenoic Acids - administration & dosage
Eicosapentaenoic Acid - administration & dosage
Female
Fish Oils - administration & dosage
Fishes
Glucose - metabolism
Glucose Tolerance Test
Humans
Male
Phospholipids - administration & dosage
Triglycerides - blood
Young Adult
Abstract
Herring roe is an underutilized source of n-3 polyunsaturated fatty acids (PUFAs) for human consumption with high phospholipid (PL) content. Studies have shown that PL may improve bioavailability of n-3 PUFAs. Arctic Nutrition's herring roe product MOPL™30 is a PL: docosahexaenoic acid (DHA)-rich fish oil mixture, with a DHA:eicosapentaenoic acid (EPA) ratio of about 3:1, which is also rich in choline. In this pilot study, we determined if MOPL30 could favorably affect plasma lipid parameters and glucose tolerance in healthy young adults.
Twenty female and one male adults, between 22 and 26 years of age, participated in the study. Participants took encapsulated MOPL30, 2.4 g/d EPA + DHA, for 14 days, and completed a three-day weighed food record before and during the capsule intake. Plasma lipids and their fatty acid (FA) composition, plasma and red blood cell (RBC) phosphatidylcholine (PC) FA composition, acylcarnitines, choline, betaine and insulin were measured before and after supplementation (n?=?21), and one and four weeks after discontinuation of supplementation (n?=?14). An oral glucose tolerance test was performed before and after supplementation.
Fasting plasma triacylglycerol and non-esterified fatty acids decreased and HDL-cholesterol increased after 14 days of MOPL30 intake (p?
Notes
Cites: J Nutr. 1996 Dec;126(12):3032-99001371
Cites: Lipids. 1997 Mar;32(3):341-59076673
Cites: Lipids. 1997 Jul;32(7):697-7059252957
Cites: J Lipid Res. 1997 Aug;38(8):1571-829300779
Cites: J Lipid Res. 1997 Oct;38(10):2012-229374124
Cites: Pharmacol Ther. 1998 Jan;77(1):59-799500159
Cites: Lipids. 1998 Feb;33(2):131-89507234
Cites: Dev Neurosci. 1999;21(2):94-10410449981
Cites: Am J Clin Nutr. 1999 Sep;70(3):383-9010479201
Cites: J Lipid Res. 1999 Oct;40(10):1867-7410508206
Cites: Best Pract Res Clin Endocrinol Metab. 2005 Sep;19(3):391-40316150382
Cites: Clin Chem Lab Med. 2005;43(10):1069-7516197300
Cites: JAMA. 2006 Oct 18;296(15):1885-9917047219
Cites: Cell Metab. 2008 Jan;7(1):45-5618177724
Cites: Cochrane Database Syst Rev. 2008;(1):CD00320518254017
Cites: Curr Med Chem. 2008;15(5):488-9818289004
Cites: J Lipid Res. 2008 Jun;49(6):1187-9418204095
Cites: Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S153-6818631994
Cites: J Agric Food Chem. 2006 May 17;54(10):3750-519127755
Cites: J Strength Cond Res. 2011 Dec;25(12):3461-7122080324
Cites: J Anim Physiol Anim Nutr (Berl). 2012 Apr;96(2):295-30621429045
Cites: Br J Nutr. 2012 Jun;107 Suppl 2:S214-2722591895
Cites: Eur J Nutr. 2012 Sep;51(6):741-5321986673
Cites: PLoS One. 2012;7(9):e4452522984522
Cites: Lipids Health Dis. 2012;11:8222738017
Cites: Int J Mol Sci. 2012;13(11):15401-1923203133
Cites: Curr Opin Clin Nutr Metab Care. 2013 Jan;16(1):102-823196816
Cites: J Clin Lipidol. 2012 Nov-Dec;6(6):573-8423312053
Cites: Curr Opin Clin Nutr Metab Care. 2013 Mar;16(2):141-923196817
Cites: Eur J Nutr. 2013 Jun;52(4):1315-2522923017
Cites: Int J Cardiol. 2013 Sep 1;167(5):1892-922622056
Cites: Postgrad Med. 2013 Nov;125(6):100-1324200766
Cites: Lipids Health Dis. 2013;12:17824304605
Cites: Cell Physiol Biochem. 2013;32(7):32-4024429813
Cites: Nutr Res. 2014 Feb;34(2):126-3324461313
Cites: J Nutr Biochem. 2014 Mar;25(3):329-3624456734
Cites: J Pharm Biomed Anal. 2014 May;93:95-10124342752
Cites: J Nutr. 1995 Nov;125(11):2851-87472666
Cites: Nutrition. 2000 Jul-Aug;16(7-8):669-7110906592
Cites: J Neurosci. 2000 Nov 15;20(22):RC10911069978
Cites: Jpn J Pharmacol. 2001 Jan;85(1):2-1011243568
Cites: J Clin Invest. 1985 Oct;76(4):1626-312997286
Cites: Eur J Clin Invest. 1989 Jun;19(3):259-642553422
PubMed ID
24886291 View in PubMed
Less detail

[Using phospholipids modified according to the method of liposome technology in the treatment of patients with chronic renal insufficiency]

https://arctichealth.org/en/permalink/ahliterature71158
Source
Lik Sprava. 2003 Oct-Nov;(7):74-6
Publication Type
Article
Author
N M Stepanova
Source
Lik Sprava. 2003 Oct-Nov;(7):74-6
Language
Ukrainian
Publication Type
Article
Keywords
Adult
Aged
Anti-Infective Agents - administration & dosage - therapeutic use
Blood Urea Nitrogen
Creatinine - blood
English Abstract
Female
Humans
Injections, Intravenous
Kidney Failure, Chronic - drug therapy
Liposomes
Male
Middle Aged
Organic Chemicals
Phospholipids - administration & dosage - therapeutic use
Severity of Illness Index
Transaminases - blood
Treatment Outcome
Abstract
The article deals with treatment of chronic renal insufficiency, which is an issue of the day. 35 patients with chronic renal insufficiency (CRI) at I-II stages irrespective of primary nosological diagnosis have been investigated. It was the first time when LIPIN was prescribed at a total dose of 20 mg/kg to improve the methods of conservative therapy. The material presents dynamics of laboratory indices of renal function over treatment with LIPIN. It was established, that LIPIN statistically reliably decreases creatinine and urea level in patient's blood, absolutely brings down transmidase blood serum activity, reduce clinical presentations of uremic gastroenteropathy as well as improves general state of health.
PubMed ID
14723142 View in PubMed
Less detail

Visualization of liver lesions in standardized video-documented ultrasonography - inter-observer agreement and effect of contrast injection.

https://arctichealth.org/en/permalink/ahliterature276126
Source
Med Ultrason. 2015 Dec;17(4):437-43
Publication Type
Article
Date
Dec-2015
Author
Carina Stenman
Robert Glavas
Joachim Davidsson
Anders Knutsson
Örjan Smedby
Source
Med Ultrason. 2015 Dec;17(4):437-43
Date
Dec-2015
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Contrast Media - administration & dosage
Female
Humans
Image Enhancement - methods
Injections, Intravenous
Liver Neoplasms - secondary - ultrasonography
Male
Middle Aged
Models, Biological
Models, Statistical
Observer Variation
Phospholipids - administration & dosage
Reference Values
Reproducibility of Results
Sensitivity and specificity
Sulfur Hexafluoride - administration & dosage
Sweden
Ultrasonography - methods - standards
Video Recording - methods - standards
Abstract
The AIM of this study was to evaluate the inter-observer agreement and effect of contrast injection on the visibility of liver lesions by radiologists reviewing ultrasound examinations acquired by a radiographer using a standardized examination protocol.
A retrospective review was conducted by two radiologists, independently of each other, of 115 ultrasound examinations of the liver with standardized examination protocols between January 2008 and December 2012. All patients included in the study had undergone surgery for colorectal cancer. Patients attending the two-year follow-up were included.
Focal findings, the most common of which were cysts, were seen in 42-43 out of the 115 patients before intravenous contrast and in 46-47 patients after intravenous contrast (p=0.012). The inter-observer agreement for focal findings was 86.1% before contrast, and 90.4% after contrast (n.s.), and the corresponding kappa values were 0.72 and 0.84, respectively.
A good inter-observer agreement between two radiologists reviewing ultrasound examinations (standardized ultrasound cine-loop method acquired by a radiographer) after surgery for colorectal cancer was obtained. Injection of contrast medium increased the visibility of liver lesions.
PubMed ID
26649336 View in PubMed
Less detail

7 records – page 1 of 1.